Vivakor Files For Mixed-Securities Shelf Of Up To $100M

-SEC Filing

byMichael Horton

January 10, 2023

1 minute read

-SEC Filing

Why Shares Of MediWound And Vericel Fell On Tuesday

By Bill Haddad

June 29, 1:10 PM

Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid Biologics License Application.

MDWD

Keybanc Maintains Overweight on EOG Resources, Raises Price Target to $98

By Benzinga Newsdesk

October 19, 5:32 AM

Keybanc analyst Leo Mariani maintains EOG Resources (NYSE:EOG) with a Overweight and raises the price target from $97 to $98.

EOG

BZ NOTE On Lottery.com Earnings/10-Q Filing From Monday Afternoon: Co. Filing Showed ‘we had neither engaged in any operations nor generated any revenues’; Sales, Income Highlighted In Press Release Related To Non-Operational Items

By Benzinga Newsdesk

November 16, 3:12 PM

"Results of Operations" shown on page 20 of the 10-Q filing: https://www.sec.gov/ix?doc=/Archives/edgar/data/1673481/000121390021059462/f10q0921_lotterycominc.htm#a_003 The company said, "We

LTRY

Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder

By Vandana Singh

April 8, 12:13 PM

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) has paused enrollment in clinical trials with BCX9930 as the Company investigates elevated serum creatinine levels seen…

BCRX

Vivakor Files For Mixed-Securities Shelf Of Up To $100M

Related Posts

Why Shares Of MediWound And Vericel Fell On Tuesday

Keybanc Maintains Overweight on EOG Resources, Raises Price Target to $98

BZ NOTE On Lottery.com Earnings/10-Q Filing From Monday Afternoon: Co. Filing Showed ‘we had neither engaged in any operations nor generated any revenues’; Sales, Income Highlighted In Press Release Related To Non-Operational Items

Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder